Impaired Exercise Capacity From PAH-CHD Most Prominent in Patients With Eisenmenger Syndrome
February 25th 2023Study findings offer insight into how exercise intolerance varies among subgroups of pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), as previous data have characterized impaired exercise tolerance among PAH-CHD as a whole.
Read More
Novel Machine Learning Model May Detect Pulmonary Hypertension Earlier
February 24th 2023Having a diagnostic model that leverages artificial intelligence could fill a gap in the pulmonary hypertension (PH) diagnostic pathway, as there are currently just 2 validated screening algorithms for PH.
Read More
FDA Approves Efanesoctocog Alfa for Hemophilia A
February 24th 2023Efanesoctocog alfa is the first factor VIII therapy to overcome the interaction with endogenous von Willebrand factor, which creates a ceiling of 8 to 19 hours on the half-life of current factor VIII replacement products, which in turn creates the need for more frequent dosing.
Read More
National Primary Care Scorecard Highlights Needs for Funding, Workforce Development, and Care Access
February 23rd 2023A newly published national report reveals a lack of financing, a shrinking workforce, gaps in care access, and nearly no federal funding for research within the US primary care space.
Read More
Population-Based Study Finds Increased Risk of Stroke, Heart Attack in Patients With MM
February 23rd 2023Individuals with multiple myeloma were 51% more likely to have a stroke and 36% more likely to have a heart attack compared with the general patient population in a large real-world assessment of arterial thrombotic events among patients with multiple myeloma in the United States.
Read More
Study Confirms Safety, Tolerability of Oral GABA for Type 1 Diabetes
February 23rd 2023A trial enrolling 97 children newly diagnosed with type 1 diabetes did not meet the primary endpoint of preservation of insulin production by beta cells, but it did show a significant decrease in fasting and clinically relevant reduced serum glucagon.
Read More
Similar Survival Rates Seen Among Black African Americans With PMF, Other Groups
February 23rd 2023The study also found, however, that transplant outcomes appear to be worse for Black African American patients who have primary myelofibrosis (PMF), although the study utilized a small sample size.
Read More
Wall Street investors pour money into developing new psychedelic treatments for mental illnesses; extreme temperature fluctuations around the country can pose health risks; Moderna and Merck's combination skin cancer treatment receives breakthrough designation from the FDA.
Read More
How Rising Insulin Costs Impacted Uninsured Populations
February 23rd 2023Researchers looked at trends in insulin usage and expenditure among insured and uninsured populations with diabetes, accounting for how the expansion of Medicaid under the Affordable Care Act may have affected these trends.
Read More
Panel Addresses How Payers, Providers Can Optimally Use Real-World Evidence to Advance Cancer Care
February 23rd 2023Utilizing real-world evidence that applies to the specific care needs of certain patient populations can promote timely decision-making among payers and providers on the use of effective cancer therapies available on the market, said panelists at the 2022 Patient-Centered Oncology Care® (PCOC) meeting.
Read More
Oncolytic Virus Therapy Shows Promising Results in Early-Stage TNBC
February 22nd 2023Results from a phase 2 study suggests that the oncolytic virus talimogene laherparepvec has potential to improve therapy responses for patients undergoing neoadjuvant chemotherapy for triple-negative breast cancer (TNBC).
Read More
Telementoring Program Linked With Improvement in Epilepsy Care Among School Nurses
February 22nd 2023School nurses reported improved knowledge and confidence in the care of students with seizures after undergoing the Project ECHO (Extension for Community Healthcare Outcomes) telementoring program for epilepsy.
Read More
Merck’s COVID-19 pill has been shown to not be successful against household infection risk; the government plans to allow states to use Medicaid funds for prison drug treatment and other services; Ozempic, used to treat type 2 diabetes, is in short supply because it’s being sought for weight loss.
Read More
Andexanet Alfa Fully Neutralizes Anticoagulation From Thrombotic Disorder Treatment
February 22nd 2023Researchers found that the anticoagulant effects of apixaban, betrixaban, edoxaban, and rivaroxaban were partially neutralized at an andexanet alfa dose of 50 mcg/mL and were completely neutralized at 100 mcg/mL.
Read More